- Home
- XFOR vs AVIR Comparison
XFOR vs AVIR Comparison
Compare XFOR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | AVIR |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 450.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | XFOR | AVIR |
|---|---|---|
| Price | $4.10 | $5.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $9.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 399.2K | 293.5K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $2.46 |
| 52 Week High | $6.63 | $6.45 |
Technical Indicators
Market Signals| Indicator | XFOR | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 45.95 |
| Support Level | $3.41 | $3.28 |
| Resistance Level | $4.54 | $6.37 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 41.67 | 14.09 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.